The basic characteristics of the included literature are detailed in Table 1, encompassing a total of 1,566 adult patients involved in phase III clinical trials of CRSwNP and four types of biological agents, namely benralizumab (anti-IL-5Rα), dupilumab (anti-IL-4Rα), mepolizumab (anti-IL-5), and tezepelumab (anti-TSLP). The gene discussed is IL5RA; the disease is chronic rhinosinusitis with nasal polyps.